Search research articles
Contact Us
Filters
Showing results (341-350 of 868) with videos related to
Page
of 87
Sort By:
Cancer Research
|
March 15, 2024
Retraction: Effects of Oligonucleotide N3'→P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells
Masaharu Akiyama, Teru Hideshima, Masood A Shammas, et al.
Leukemia
|
June 12, 2019
The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma
Sophia Adamia, Ivane Abiatari, Samir B Amin, et al.
BMC Genomics
|
October 18, 2014
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
Paul Dowling, Catriona Hayes, Kay Reen Ting, et al.
Frontiers in Oncology
|
February 25, 2022
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
Claudio Cerchione, Saad Z Usmani, A Keith Stewart, et al.
Cancer Research
|
March 15, 2024
Retraction: Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein
Masaharu Akiyama, Teru Hideshima, Toshiaki Hayashi, et al.
Blood
|
October 24, 2002
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Teru Hideshima, Constantine Mitsiades, Masaharu Akiyama, et al.
The Journal of Biological Chemistry
|
December 26, 2001
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation
Klaus Podar, Yu-Tzu Tai, Boris K Lin, et al.
Cancer Research
|
January 9, 2003
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein
Masaharu Akiyama, Teru Hideshima, Toshiaki Hayashi, et al.
Cancer
|
February 14, 2006
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial
Paul G Richardson, Bart Barlogie, James Berenson, et al.
Seminars in Hematology
|
April 25, 2009
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib
Constantine S Mitsiades, Teru Hideshima, Dharminder Chauhan, et al.
Page
of 87
Search research articles
Search
Showing results (341-350 of 868) with videos related to
Sort By:
Page
of 87
Cancer Research
|
March 15, 2024
Retraction: Effects of Oligonucleotide N3'→P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells
Masaharu Akiyama, Teru Hideshima, Masood A Shammas, et al.
Leukemia
|
June 12, 2019
The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma
Sophia Adamia, Ivane Abiatari, Samir B Amin, et al.
BMC Genomics
|
October 18, 2014
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
Paul Dowling, Catriona Hayes, Kay Reen Ting, et al.
Frontiers in Oncology
|
February 25, 2022
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
Claudio Cerchione, Saad Z Usmani, A Keith Stewart, et al.
Cancer Research
|
March 15, 2024
Retraction: Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein
Masaharu Akiyama, Teru Hideshima, Toshiaki Hayashi, et al.
Blood
|
October 24, 2002
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Teru Hideshima, Constantine Mitsiades, Masaharu Akiyama, et al.
The Journal of Biological Chemistry
|
December 26, 2001
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation
Klaus Podar, Yu-Tzu Tai, Boris K Lin, et al.
Cancer Research
|
January 9, 2003
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein
Masaharu Akiyama, Teru Hideshima, Toshiaki Hayashi, et al.
Cancer
|
February 14, 2006
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial
Paul G Richardson, Bart Barlogie, James Berenson, et al.
Seminars in Hematology
|
April 25, 2009
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib
Constantine S Mitsiades, Teru Hideshima, Dharminder Chauhan, et al.
Page
of 87